IPSASB unveils the world's first dedicated climate reporting standard for governments and public bodies, mandating disclosures from 2028 to illuminate financial risks and opportunities.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
Vice President Sara Duterte faces renewed impeachment efforts in the Philippine Congress, centered on allegations of misusing millions in confidential funds. The move reignites political tensions in a nation grappling with the legacies of powerful political dynasties.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Morris Chang, the 94-year-old founder of Taiwan Semiconductor Manufacturing Co., made his first public appearance in over a year at a private dinner in Taipei with Nvidia CEO Jensen Huang. The meeting, which ended months of speculation about Chang's health and public role, also served as a platform to reaffirm TSMC's central position in the global chip supply chain.
Despite vocal campaigns by Elon Musk and other tech leaders urging companies to abandon Delaware, new data reveals the state experienced a significant surge in corporate formations in 2025, solidifying its dominant position.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
Identifying companies with sustainable growth engines is a perennial challenge for investors. We analyze three firms—Vertiv, Ares Management, and Halozyme Therapeutics—that are expanding their competitive moats and delivering robust revenue growth, offering potential shelter in uncertain times.
While the sub-$10 stock universe offers potential for significant returns, it demands rigorous scrutiny. We analyze one company with a compelling growth thesis and two others where investors should proceed with caution.
A coalition of major international NGOs is refusing to comply with Israeli orders to hand over detailed staff information, calling it a safety risk and an obstruction of aid, as tensions escalate following the expulsion of Médecins Sans Frontières.
Amid a contentious federal immigration operation, Minneapolis residents report heightened tensions and an increased security presence, contradicting official promises of de-escalation. The arrests of journalists and unresolved fatal shootings have intensified scrutiny and community-led resistance.
A major advisory firm's complete exit from a short-term Treasury ETF is sparking debate on whether institutional investors are moving idle cash into higher-growth opportunities.
Amidst a cautiously optimistic economic backdrop in the Eurozone, we spotlight three lesser-known companies with strong fundamentals that investors may be overlooking. From medical supplies to IT services, these firms demonstrate resilience and potential for the year ahead.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Merck & Co. shares have delivered impressive multi-year returns, climbing over 80% in the past five years. Yet, a deep dive into its valuation metrics suggests the market may still be underestimating the pharmaceutical leader's intrinsic value, presenting a potential opportunity for investors.
As financial institutions grapple with aging core systems like Gen, experts warn that deferring modernization in hopes of a future AI fix is compounding costs, risks, and missed opportunities in a rapidly evolving digital landscape.
While analyst price targets often paint a rosy picture, a closer look reveals a more nuanced reality. We examine one favored stock with solid fundamentals and two others where the Street's optimism may be overlooking critical risks.
While growth often requires investment, a sustained negative free cash flow can signal deep-seated issues. We examine three well-known companies where the cash burn warrants a cautious approach from investors.
The probate process can drain an estate's assets and burden heirs for years. Financial and legal experts outline practical steps families can take now to ensure a smoother transfer of wealth.
